Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01669525 · ClinicalTrials.gov registry record
Placental Growth and Adverse Pregnancy Outcomes
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 1,043
- Enrollment target
NCT01669525: Completed study, sponsored by University of Pennsylvania.
NCT01669525 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 1,043 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01669525 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 1,043 participants
- Enrollment target
Study Summary
The purpose of this study to determine if measurement of maternal serum biomarkers and evaluation of the placenta by ultrasound can improve prediction of adverse pregnancy outcomes.
Primary Outcome
Neonatal weight and length are recorded at birth. This information will be retrieved from the medical record post partum.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,043 participants |
| Start Date | 2009-11 |
| Est. Completion | 2016-06 |
What the finished NCT01669525 record still lists
NCT01669525 is an observational study that tracks outcomes without assigning an intervention. Its 1,043 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01669525 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01669525 about?
NCT01669525 is a clinical study titled "Placental Growth and Adverse Pregnancy Outcomes". The purpose of this study to determine if measurement of maternal serum biomarkers and evaluation of the placenta by ultrasound can improve prediction of adverse pregnancy outcomes.
What is the current status of trial NCT01669525?
This trial is currently completed. The enrollment target is 1,043 participants. The study started on 2009-11. Estimated completion is 2016-06.
Who is sponsoring clinical trial NCT01669525?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04685616 · 1,042 participants · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- NCT06564948 · 1,040 participants · NA
Treatment for Individuals Interacting with the Criminal Justice System
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia